The CD8F1 murine breeding and spontaneous tumor holding colonies located at the St. Anthony's Research Center will serve as a Core Component for this Research Program Spontaneous, autochthonous tumor-bearing transplants will be provided for Research Project I (Experimental Chemotherapy), Research Project 2 (Biochemical Studies), and Research Project 3 (Monoclonal Antibody Studies). In addition, samples of plasma, normal tissue and tumor tissue from animals undergoing experimental chemotherapy will be supplied for comparative biochemical and pharmacokinetic studies with human samples in Research Project 4 (Clinical Studies). The Colony consists of two inbred lines (BALB/c and DBA/8), a first generation hybrid (CD8F1), and facilities for holding hybrid females for tumor development (average tumor incidence of approximately 75% at 10 months of age). Approximately 650 CD8F1 mice will be weaned each week. Of these, 500 will be set aside to age for additional 11/2 to 2 months to be used as primary CD8F1 breast tumor transplant recipients. To produce the required 100 spontaneous, autochthonous tumor-bearing CD8F1 females per week, 126 CD8F1 female weanlings (+21 CD8F1 males) are placed in the tumor holding colony each week, where they are observed for tumor development. Caretaking functions for all mice (breeding colonies, spontaneous tumor holding colony, mice being aged for experimentation, and tumor-bearing mice undergoing experimentation) will be the responsibility of the Animal Colony Core Component. CD8F1 tumors arise spontaneously in mid-to-late middle age in a high percentage of CD8F1 female mice. They are morphologically similar to human breast tumors, and metastasize spontaneously. Like human tumors, thy have a relatively slow cell cycle time of 3-5 days which is considerably longer than the 24 hour cell cycle time of transplantable murine tumors. Like human tumors, they show a vast degree of heterogeneity of many characteristics including growth rate and chemotherapeutic sensitivity. Like human tumors, and presumably because of their heterogeneity, they are not cureable with any currently available single or multiple agent chemotherapy. They show a remarkable 100% corelation in chemotherapeutic sensitivity to drugs which are considered to be active against human breast caner. Because of these many parallels with the human disease, the CD8F1 spontaneous mammary tumor system provides an appropriate animal model for the preclinical development of combination chemotherapy for human cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA025842-09
Application #
3816338
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1989
Total Cost
Indirect Cost
Name
St. Vincent Catholic Medical Center Nursing
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
11432
Martin, D S; Spriggs, D; Koutcher, J A (2001) A concomitant ATP-depleting strategy markedly enhances anticancer agent activity. Apoptosis 6:125-31
Nord, L D; Stolfi, R L; Alfieri, A A et al. (1997) Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion. Cancer Chemother Pharmacol 40:376-84
Martin, D S; Schwartz, G K (1997) Chemotherapeutically induced DNA damage, ATP depletion, and the apoptotic biochemical cascade. Oncol Res 9:1-5
Koutcher, J A; Alfieri, A A; Tsai, J C et al. (1997) Evaluation of chemotherapy and radiation enhancement and 31P NMR spectral changes induced by biochemical modulation. Cancer Invest 15:111-20
Koutcher, J A; Alfieri, A A; Thaler, H et al. (1997) Radiation enhancement by biochemical modulation and 5-fluorouracil. Int J Radiat Oncol Biol Phys 39:1145-52
Martin, D S; Stolfi, R L; Colofiore, J R (1997) Perspective: the chemotherapeutic relevance of apoptosis and a proposed biochemical cascade for chemotherapeutically induced apoptosis. Cancer Invest 15:372-81
Street, J C; Alfieri, A A; Koutcher, J A (1997) Quantitation of metabolic and radiobiological effects of 6-aminonicotinamide in RIF-1 tumor cells in vitro. Cancer Res 57:3956-62
Kelsen, D P; Martin, D; O'Neil, J et al. (1997) Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. J Clin Oncol 15:1511-7
Street, J C; Koutcher, J A (1997) Effect of radiotherapy and chemotherapy on composition of tumor membrane phospholipids. Lipids 32:45-9
Stolfi, R L; Colofiore, J R; Nord, L D et al. (1996) Enhanced antitumor activity of an adriamycin + 5-fluorouracil combination when preceded by biochemical modulation. Anticancer Drugs 7:100-4

Showing the most recent 10 out of 48 publications